Selective induction of apoptosis by HMG-CoA-reductase inhibitors in hepatoma cells is dependent on p53 expression

Kah, Janine; Wüstenberg, A; Keller, AD; Sirma, Hüseyin; Tiegs, Gisa; Sass, G; Dandri, Maura

doi:10.1055/s-0031-1295979

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…198 199 This effect was achieved by inhibiting the oncoproteins, Skp2, and the signal transducer and activator of transcription 3, while upregulating AMP-associated protein kinase, which modulates metabolic homeostasis and suppresses tumor cell proliferation. 198 200 201 Alternatively, statin targets Notch gene family by upregulating Notch1, the primary signaling receptor responsible for the regulation of proteolysis, which in turn regulates tumor growth via an Akt-dependent signaling pathway. 202 203 Regulation of Akt pathway in HCC and statin use is not new; statin inhibits Akt and YAP signaling cascade, both of which are involved in hepatic fibrogenesis and carcinogenesis, through stabilization of r etinoid X r eceptor-α, a known antiproliferative chemotherapeutic target.…”

Section: Statin and Hepatocellular Carcinomamentioning

confidence: 99%

Statins in Chronic Liver Disease: Review of the Literature and Future Role

Pham,

Benhammou

2024

Semin Liver Dis

View full text Add to dashboard Cite

Chronic liver disease (CLD) is a major contributor to global mortality, morbidity, and healthcare burden. Progress in pharmacotherapeutic for CLD management is lagging given its impact on the global population. While statins are indicated for the management of dyslipidemia and cardiovascular disease, their role in CLD prevention and treatment is emerging. Beyond their lipid lowering effects, their liver-related mechanisms of action are multifactorial and include anti-inflammatory, anti-proliferative, and immune-protective effects. In this review, we highlight what is known about the clinical benefits of statins in viral and non-viral etiologies of CLD and HCC, and explore key mechanisms and pathways targeted by statins. While their benefits may span the spectrum of CLD and potentially HCC treatment, their role in CLD chemoprevention is likely to have the largest impact. As emerging data suggest that genetic variants may impact their benefits, the role of statins in precision hepatology will need to be further explored.

show abstract